Equities research analysts expect that The Cooper Companies, Inc. (NYSE:COO – Get Rating) will post earnings of $3.45 per share for the current quarter, according to Zacks. Seven analysts have issued estimates for Cooper Companies’ earnings. The highest EPS estimate is $3.51 and the lowest is $3.41. Cooper Companies posted earnings of $3.38 per share during the same quarter last year, which would indicate a positive year over year growth rate of 2.1%. The firm is scheduled to report its next earnings results on Monday, January 1st.
On average, analysts expect that Cooper Companies will report full-year earnings of $14.09 per share for the current fiscal year, with EPS estimates ranging from $13.90 to $14.45. For the next year, analysts expect that the company will report earnings of $15.97 per share, with EPS estimates ranging from $15.50 to $16.39. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Cooper Companies.
Cooper Companies (NYSE:COO – Get Rating) last issued its quarterly earnings results on Thursday, March 3rd. The medical device company reported $3.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.10 by $0.14. Cooper Companies had a net margin of 31.00% and a return on equity of 9.89%. The firm had revenue of $787.20 million for the quarter, compared to analyst estimates of $739.30 million. During the same period last year, the company posted $3.17 EPS. Cooper Companies’s quarterly revenue was up 15.7% compared to the same quarter last year.
In other Cooper Companies news, Director Jody S. Lindell sold 700 shares of the company’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $421.04, for a total transaction of $294,728.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Robert S. Weiss sold 13,039 shares of the company’s stock in a transaction on Tuesday, March 29th. The stock was sold at an average price of $415.24, for a total value of $5,414,314.36. The disclosure for this sale can be found here. Insiders sold 19,646 shares of company stock valued at $8,195,614 over the last quarter. 1.70% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. Wolff Wiese Magana LLC raised its stake in shares of Cooper Companies by 110.3% in the third quarter. Wolff Wiese Magana LLC now owns 61 shares of the medical device company’s stock valued at $25,000 after acquiring an additional 32 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Cooper Companies in the third quarter valued at $26,000. Liberty Wealth Management LLC raised its stake in Cooper Companies by 1,340.0% in the third quarter. Liberty Wealth Management LLC now owns 72 shares of the medical device company’s stock valued at $30,000 after buying an additional 67 shares in the last quarter. PrairieView Partners LLC acquired a new stake in Cooper Companies in the fourth quarter valued at $33,000. Finally, O Shaughnessy Asset Management LLC raised its stake in Cooper Companies by 66.7% in the third quarter. O Shaughnessy Asset Management LLC now owns 85 shares of the medical device company’s stock valued at $35,000 after buying an additional 34 shares in the last quarter. Institutional investors own 98.00% of the company’s stock.
NYSE:COO opened at $406.96 on Friday. Cooper Companies has a 12 month low of $368.78 and a 12 month high of $463.59. The stock has a 50 day moving average of $404.71 and a two-hundred day moving average of $406.14. The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of 0.34. The firm has a market cap of $20.06 billion, a P/E ratio of 21.59, a price-to-earnings-growth ratio of 2.66 and a beta of 0.85.
Cooper Companies Company Profile (Get Rating)
The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific.
- Get a free copy of the StockNews.com research report on Cooper Companies (COO)
- 3 Best Recession-Resistant, Cost-Conscious Retail Stocks to Take a Look at Right Now
- Simply Good Foods Stock is a Healthy Defensive Play
- Poor Timing Will Put Delta Air Lines on Standby For Risk-Off Investors
- 3 Tech Stocks to Buy for Retirement
- Schlumberger Analyst Coverage Drives Market Higher
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.